Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials
Abstract Background Given the broad definition of an acute exacerbation of IPF, it is likely that acute exacerbations are heterogeneous in their aetiology, severity and clinical course. We used pooled data from the INPULSIS® trials of nintedanib versus placebo to investigate whether acute exacerbati...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-04-01
|
Series: | Respiratory Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12931-019-1037-7 |
id |
doaj-03779ee31c434909ac06bb540a2bc7c5 |
---|---|
record_format |
Article |
spelling |
doaj-03779ee31c434909ac06bb540a2bc7c52020-11-25T02:28:54ZengBMCRespiratory Research1465-993X2019-04-012011710.1186/s12931-019-1037-7Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trialsMichael Kreuter0Harald Koegler1Matthias Trampisch2Silke Geier3Luca Richeldi4Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Care Medicine, Thoraxklinik, University of HeidelbergBoehringer Ingelheim International GmbHBoehringer Ingelheim International GmbHBoehringer Ingelheim International GmbHUniversità Cattolica del Sacro Cuore, Fondazione Policlinico A. GemelliAbstract Background Given the broad definition of an acute exacerbation of IPF, it is likely that acute exacerbations are heterogeneous in their aetiology, severity and clinical course. We used pooled data from the INPULSIS® trials of nintedanib versus placebo to investigate whether acute exacerbations reported as serious adverse events were associated with higher mortality than those reported as non-serious adverse events and to assess the effect of nintedanib on these types of events. Methods Adverse events considered by an investigator to be an acute exacerbation were adjudicated as a confirmed acute exacerbation, suspected acute exacerbation, or not an acute exacerbation. Time to first investigator-reported acute exacerbation or confirmed/suspected acute exacerbation reported as a serious adverse event or non-serious adverse event over the 52-week treatment period was assessed post-hoc. Deaths were assessed based on data collected over the 52-week treatment period. Results Of 63 patients who had ≥1 investigator-reported acute exacerbation, 48 (76.2%) had a first acute exacerbation reported as a serious adverse event. Thirty-six (3.4%) patients had ≥1 confirmed/suspected acute exacerbation, of whom 31 had a first event reported as a serious adverse event. Investigator-reported acute exacerbations reported as serious adverse events occurred in 23 patients in the nintedanib group and 26 in the placebo group. Confirmed/suspected acute exacerbations reported as serious adverse events occurred in 10 and 21 patients in these groups, respectively. Nintedanib significantly reduced the risk of a first acute exacerbation reported as a serious adverse event (HR 0.57 [95% CI: 0.32, 0.99]; p = 0.0476) and the risk of a first confirmed/suspected acute exacerbation reported as a serious adverse event (HR 0.30 [95% CI: 0.14, 0.64]; p = 0.0019) versus placebo. A higher proportion of patients with investigator-reported acute exacerbations reported as serious adverse events died than patients with acute exacerbations reported as non-serious adverse events (61.2% versus 7.1%). Conclusion Different severities of acute exacerbation of IPF may exist. Acute exacerbations reported as serious adverse events in the INPULSIS® trials were associated with high mortality. Nintedanib significantly reduced the risk of acute exacerbations reported as serious adverse events. Trial registration ClinicalTrials.gov NCT01335464 and NCT01335477.http://link.springer.com/article/10.1186/s12931-019-1037-7NintedanibTyrosine kinase inhibitorSerious adverse eventsDisease progressionTreatment outcome |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Michael Kreuter Harald Koegler Matthias Trampisch Silke Geier Luca Richeldi |
spellingShingle |
Michael Kreuter Harald Koegler Matthias Trampisch Silke Geier Luca Richeldi Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials Respiratory Research Nintedanib Tyrosine kinase inhibitor Serious adverse events Disease progression Treatment outcome |
author_facet |
Michael Kreuter Harald Koegler Matthias Trampisch Silke Geier Luca Richeldi |
author_sort |
Michael Kreuter |
title |
Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials |
title_short |
Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials |
title_full |
Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials |
title_fullStr |
Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials |
title_full_unstemmed |
Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials |
title_sort |
differing severities of acute exacerbations of idiopathic pulmonary fibrosis (ipf): insights from the inpulsis® trials |
publisher |
BMC |
series |
Respiratory Research |
issn |
1465-993X |
publishDate |
2019-04-01 |
description |
Abstract Background Given the broad definition of an acute exacerbation of IPF, it is likely that acute exacerbations are heterogeneous in their aetiology, severity and clinical course. We used pooled data from the INPULSIS® trials of nintedanib versus placebo to investigate whether acute exacerbations reported as serious adverse events were associated with higher mortality than those reported as non-serious adverse events and to assess the effect of nintedanib on these types of events. Methods Adverse events considered by an investigator to be an acute exacerbation were adjudicated as a confirmed acute exacerbation, suspected acute exacerbation, or not an acute exacerbation. Time to first investigator-reported acute exacerbation or confirmed/suspected acute exacerbation reported as a serious adverse event or non-serious adverse event over the 52-week treatment period was assessed post-hoc. Deaths were assessed based on data collected over the 52-week treatment period. Results Of 63 patients who had ≥1 investigator-reported acute exacerbation, 48 (76.2%) had a first acute exacerbation reported as a serious adverse event. Thirty-six (3.4%) patients had ≥1 confirmed/suspected acute exacerbation, of whom 31 had a first event reported as a serious adverse event. Investigator-reported acute exacerbations reported as serious adverse events occurred in 23 patients in the nintedanib group and 26 in the placebo group. Confirmed/suspected acute exacerbations reported as serious adverse events occurred in 10 and 21 patients in these groups, respectively. Nintedanib significantly reduced the risk of a first acute exacerbation reported as a serious adverse event (HR 0.57 [95% CI: 0.32, 0.99]; p = 0.0476) and the risk of a first confirmed/suspected acute exacerbation reported as a serious adverse event (HR 0.30 [95% CI: 0.14, 0.64]; p = 0.0019) versus placebo. A higher proportion of patients with investigator-reported acute exacerbations reported as serious adverse events died than patients with acute exacerbations reported as non-serious adverse events (61.2% versus 7.1%). Conclusion Different severities of acute exacerbation of IPF may exist. Acute exacerbations reported as serious adverse events in the INPULSIS® trials were associated with high mortality. Nintedanib significantly reduced the risk of acute exacerbations reported as serious adverse events. Trial registration ClinicalTrials.gov NCT01335464 and NCT01335477. |
topic |
Nintedanib Tyrosine kinase inhibitor Serious adverse events Disease progression Treatment outcome |
url |
http://link.springer.com/article/10.1186/s12931-019-1037-7 |
work_keys_str_mv |
AT michaelkreuter differingseveritiesofacuteexacerbationsofidiopathicpulmonaryfibrosisipfinsightsfromtheinpulsistrials AT haraldkoegler differingseveritiesofacuteexacerbationsofidiopathicpulmonaryfibrosisipfinsightsfromtheinpulsistrials AT matthiastrampisch differingseveritiesofacuteexacerbationsofidiopathicpulmonaryfibrosisipfinsightsfromtheinpulsistrials AT silkegeier differingseveritiesofacuteexacerbationsofidiopathicpulmonaryfibrosisipfinsightsfromtheinpulsistrials AT lucaricheldi differingseveritiesofacuteexacerbationsofidiopathicpulmonaryfibrosisipfinsightsfromtheinpulsistrials |
_version_ |
1724835788576784384 |